Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia.

Yamazaki M, Harada K, Yamamoto N, Yarimizu J, Okabe M, Shimada T, Ni K, Matsuoka N.

Eur Neuropsychopharmacol. 2014 Jul 27. pii: S0924-977X(14)00206-5. doi: 10.1016/j.euroneuro.2014.07.009. [Epub ahead of print]

PMID:
25108314
[PubMed - as supplied by publisher]
Free Article
2.

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.

Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N.

Eur J Pharmacol. 2012 Jun 15;685(1-3):59-69. doi: 10.1016/j.ejphar.2012.04.013. Epub 2012 Apr 20.

PMID:
22542656
[PubMed - indexed for MEDLINE]
3.

SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain.

Thomas DR, Soffin EM, Roberts C, Kew JN, de la Flor RM, Dawson LA, Fry VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan JJ.

Neuropharmacology. 2006 Sep;51(3):566-77. Epub 2006 Jul 17.

PMID:
16846620
[PubMed - indexed for MEDLINE]
4.

KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia.

Park WK, Jeong D, Cho H, Lee SJ, Cha MY, Pae AN, Choi KI, Koh HY, Kong JY.

Pharmacol Biochem Behav. 2005 Oct;82(2):361-72. Epub 2005 Oct 10.

PMID:
16216322
[PubMed - indexed for MEDLINE]
5.

Spinal 5-HT₅A receptors mediate 5-HT-induced antinociception in several pain models in rats.

Muñoz-Islas E, Vidal-Cantú GC, Bravo-Hernández M, Cervantes-Durán C, Quiñonez-Bastidas GN, Pineda-Farias JB, Barragán-Iglesias P, Granados-Soto V.

Pharmacol Biochem Behav. 2014 May;120:25-32. doi: 10.1016/j.pbb.2014.02.001. Epub 2014 Feb 8.

PMID:
24517902
[PubMed - in process]
6.

Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.

Meltzer HY, Rajagopal L, Huang M, Oyamada Y, Kwon S, Horiguchi M.

Int J Neuropsychopharmacol. 2013 Nov;16(10):2181-94. doi: 10.1017/S1461145713000928. Review.

PMID:
24099265
[PubMed - indexed for MEDLINE]
7.

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23.

PMID:
20569520
[PubMed - indexed for MEDLINE]
8.

Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors.

Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T.

Psychopharmacology (Berl). 2009 Jan;202(1-3):315-28. doi: 10.1007/s00213-008-1240-6. Epub 2008 Aug 6.

PMID:
18679658
[PubMed - indexed for MEDLINE]
9.

Predictive validity of a MK-801-induced cognitive impairment model in mice: implications on the potential limitations and challenges of modeling cognitive impairment associated with schizophrenia preclinically.

Brown JW, Rueter LE, Zhang M.

Prog Neuropsychopharmacol Biol Psychiatry. 2014 Mar 3;49:53-62. doi: 10.1016/j.pnpbp.2013.11.008. Epub 2013 Nov 19.

PMID:
24269664
[PubMed - in process]
10.

Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia.

Pouzet B, Didriksen M, Arnt J.

Pharmacol Biochem Behav. 2002 Apr;71(4):635-43.

PMID:
11888555
[PubMed - indexed for MEDLINE]
11.

Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.

Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J.

Psychopharmacology (Berl). 2010 Jan;208(1):23-36. doi: 10.1007/s00213-009-1702-5. Epub 2009 Oct 23.

PMID:
19851757
[PubMed - indexed for MEDLINE]
12.

Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.

Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.

Eur Neuropsychopharmacol. 2008 Jun;18(6):448-54. doi: 10.1016/j.euroneuro.2007.11.005. Epub 2007 Dec 31.

PMID:
18164909
[PubMed - indexed for MEDLINE]
13.

Nicotinic-antipsychotic drug interactions and cognitive function.

Levin ED, Rezvani AH.

EXS. 2006;98:185-205. Review.

PMID:
17019889
[PubMed - indexed for MEDLINE]
14.

SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4- [5-(4-fluoro-phenyl)-pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug.

McCreary AC, Glennon JC, Ashby CR Jr, Meltzer HY, Li Z, Reinders JH, Hesselink MB, Long SK, Herremans AH, van Stuivenberg H, Feenstra RW, Kruse CG.

Neuropsychopharmacology. 2007 Jan;32(1):78-94. Epub 2006 May 17.

PMID:
16710314
[PubMed - indexed for MEDLINE]
Free Article
15.

Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice.

Gleason SD, Shannon HE.

Psychopharmacology (Berl). 1997 Jan;129(1):79-84.

PMID:
9122367
[PubMed - indexed for MEDLINE]
16.

Animal model of schizophrenia: dysfunction of NMDA receptor-signaling in mice following withdrawal from repeated administration of phencyclidine.

Nabeshima T, Mouri A, Murai R, Noda Y.

Ann N Y Acad Sci. 2006 Nov;1086:160-8. Review.

PMID:
17185514
[PubMed - indexed for MEDLINE]
17.

Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression.

Kassai F, Schlumberger C, Kedves R, Pietraszek M, Jatzke C, Lendvai B, Gyertyán I, Danysz W.

Behav Pharmacol. 2012 Aug;23(4):397-406. doi: 10.1097/FBP.0b013e3283565248.

PMID:
22785385
[PubMed - indexed for MEDLINE]
18.
19.

Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.

Tada M, Shirakawa K, Matsuoka N, Mutoh S.

Psychopharmacology (Berl). 2004 Oct;176(1):94-100. Epub 2004 Apr 9.

PMID:
15083255
[PubMed - indexed for MEDLINE]
20.

Egis-11150: a candidate antipsychotic compound with procognitive efficacy in rodents.

Gacsályi I, Nagy K, Pallagi K, Lévay G, Hársing LG Jr, Móricz K, Kertész S, Varga P, Haller J, Gigler G, Szénási G, Barkóczy J, Bíró J, Spedding M, Antoni FA.

Neuropharmacology. 2013 Jan;64:254-63. doi: 10.1016/j.neuropharm.2012.07.017. Epub 2012 Jul 21.

PMID:
22824189
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk